The last time this column looked at Aveva in December, it recommended that investors bank profits and offload some of their holdings in the industrial software developer (Miles Costello writes).
The shares have since fallen by just over 10 per cent, in no small part thanks to yesterday’s reported sharp drop in first-half profits, which pushed the price sharply lower.
It’s hardly a stunning piece of prescience, though. No one could have predicted the onset of the coronavirus and the disruptions to industry that it would cause. And, relative to much of the rest of the market, the group’s shares have fared extremely well. Is it time to buy back in again on the weakness?
Aveva was spun out of the University of Cambridge in
